ATE415632T1 - Verfahren zur diagnose und behandlung von morbus crohn - Google Patents
Verfahren zur diagnose und behandlung von morbus crohnInfo
- Publication number
- ATE415632T1 ATE415632T1 AT05809109T AT05809109T ATE415632T1 AT E415632 T1 ATE415632 T1 AT E415632T1 AT 05809109 T AT05809109 T AT 05809109T AT 05809109 T AT05809109 T AT 05809109T AT E415632 T1 ATE415632 T1 AT E415632T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- crohn
- treatment
- diagnosis
- relates
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0410865A FR2876798A1 (fr) | 2004-10-14 | 2004-10-14 | Diagnostic et traitement de la maladie de crohn |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE415632T1 true ATE415632T1 (de) | 2008-12-15 |
Family
ID=34951162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05809109T ATE415632T1 (de) | 2004-10-14 | 2005-10-13 | Verfahren zur diagnose und behandlung von morbus crohn |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9176131B2 (de) |
| EP (1) | EP1800134B1 (de) |
| JP (1) | JP4896883B2 (de) |
| AT (1) | ATE415632T1 (de) |
| CA (1) | CA2582228C (de) |
| DE (1) | DE602005011316D1 (de) |
| DK (1) | DK1800134T3 (de) |
| ES (1) | ES2317327T3 (de) |
| FR (1) | FR2876798A1 (de) |
| WO (1) | WO2006040481A2 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012109263A1 (en) | 2011-02-07 | 2012-08-16 | The Washington University | Mannoside compounds and methods of use thereof |
| EP2377883A1 (de) | 2010-04-15 | 2011-10-19 | Universite d'Auvergne Clermont I | Antagonisten zur Vorbeugung oder Behandlung von entzündlicher Darmerkrankung, speziell von Morbus Crohn |
| TWI626247B (zh) | 2012-12-18 | 2018-06-11 | 維泰克斯製藥公司 | 用於治療細菌感染之甘露糖衍生物 |
| WO2014165107A2 (en) | 2013-03-12 | 2014-10-09 | Vertex Pharmaceuticals Incorporated | Mannose derivatives for treating bacterial infections |
| EP3003322B1 (de) | 2013-05-30 | 2023-09-13 | Washington University | Mannosederivate und deren verwendung bei der behandlung von bakteriellen infektionen |
| CN104459154B (zh) * | 2014-12-09 | 2016-04-27 | 临沂大学 | 一种新型人工模拟酶的合成及对糖基检测方法的构建 |
| AU2017238392A1 (en) | 2016-03-23 | 2018-09-27 | Fimbrion Therapeutics, Inc. | Mannose-derived antagonists of FimH useful for treating disease |
| KR102373502B1 (ko) * | 2018-05-14 | 2022-03-11 | 주식회사 금호에이치티 | 골수유래억제세포 관련 질환의 예방 및 치료 용도 |
| UY38293A (es) | 2018-07-10 | 2020-05-29 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos y composiciones de c-manósido antagonistas de fimh |
| US12297223B2 (en) | 2019-05-07 | 2025-05-13 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| WO2020254369A1 (en) | 2019-06-19 | 2020-12-24 | Glaxosmithkline Intellectual Property Development Limited | Substituted biphenyl or phenylheteroaryl-mannosides as antagonists of fimh |
| EP3757572A1 (de) * | 2019-06-27 | 2020-12-30 | Centre National de la Recherche Scientifique | Nachweis von pathogenen bakterien durch chemisch funktionalisierte cellulose |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5308838A (en) * | 1982-05-07 | 1994-05-03 | Carrington Laboratories, Inc. | Uses of aloe products |
| JP3342749B2 (ja) * | 1993-09-20 | 2002-11-11 | 積水化学工業株式会社 | 糖化蛋白の測定方法 |
| EP0747705A1 (de) * | 1995-06-09 | 1996-12-11 | Bayer Corporation | Spezifische Bestimmung von NCA 90 Glykoprotein im Blut eines Krebspatienten |
| DE69631381T2 (de) * | 1995-11-22 | 2004-10-21 | Univ Montana State | Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen |
| US5874233A (en) * | 1996-04-12 | 1999-02-23 | Cedars-Sinai Medical Center | Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis |
| US6290959B1 (en) * | 1996-10-24 | 2001-09-18 | New York University | Method for screening compounds for inhibiting bacterial attachment to host cell receptors |
| NL1010770C2 (nl) * | 1998-12-09 | 2000-06-13 | Nutricia Nv | Preparaat dat oligosacchariden en probiotica bevat. |
| US6942981B1 (en) * | 1999-05-14 | 2005-09-13 | Arbor Vita Corporation | Method of determining interactions with PDZ-domain polypeptides |
| US7138237B1 (en) * | 2000-05-19 | 2006-11-21 | Cedars-Sinai Medical Center | Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen |
| EP1381688A1 (de) * | 2001-04-25 | 2004-01-21 | N.V. Nutricia | Verfahren zur fermentativen herstellung eines gesundheitsfördernden produktes |
| JP4947851B2 (ja) * | 2001-06-07 | 2012-06-06 | 信紘 佐藤 | 潰瘍性大腸炎治療薬 |
| WO2003002117A2 (en) * | 2001-06-29 | 2003-01-09 | Astion Development A/S | Niaciamide and derivatives in combination with aminosugar |
| AU2002367696A1 (en) * | 2001-10-12 | 2003-09-09 | Mcgill University | Enhanced immunization and suppression of oral tolerance |
| US20040005304A1 (en) * | 2002-07-08 | 2004-01-08 | Mak Wood, Inc. | Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions |
| US8247231B2 (en) * | 2003-07-31 | 2012-08-21 | Wilson Constance N | Methods and compositions for producing antigenic responses |
| US7799328B2 (en) * | 2004-12-23 | 2010-09-21 | Biocodex | Method for treating weight loss in patients suffering from inflammatory bowel diseases |
| CN101918536B (zh) * | 2007-12-26 | 2013-07-03 | 勒萨弗尔公司 | 用于人类和/或动物的营养的组合物、它们的应用和酵母菌 |
-
2004
- 2004-10-14 FR FR0410865A patent/FR2876798A1/fr not_active Withdrawn
-
2005
- 2005-10-13 DK DK05809109T patent/DK1800134T3/da active
- 2005-10-13 WO PCT/FR2005/002538 patent/WO2006040481A2/fr not_active Ceased
- 2005-10-13 US US11/577,264 patent/US9176131B2/en not_active Expired - Fee Related
- 2005-10-13 ES ES05809109T patent/ES2317327T3/es not_active Expired - Lifetime
- 2005-10-13 AT AT05809109T patent/ATE415632T1/de not_active IP Right Cessation
- 2005-10-13 EP EP05809109A patent/EP1800134B1/de not_active Expired - Lifetime
- 2005-10-13 CA CA2582228A patent/CA2582228C/fr not_active Expired - Fee Related
- 2005-10-13 JP JP2007536221A patent/JP4896883B2/ja not_active Expired - Fee Related
- 2005-10-13 DE DE602005011316T patent/DE602005011316D1/de not_active Expired - Lifetime
-
2015
- 2015-09-30 US US14/870,179 patent/US20160091501A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008517261A (ja) | 2008-05-22 |
| WO2006040481A3 (fr) | 2006-08-31 |
| ES2317327T3 (es) | 2009-04-16 |
| US9176131B2 (en) | 2015-11-03 |
| US20100015600A1 (en) | 2010-01-21 |
| FR2876798A1 (fr) | 2006-04-21 |
| DK1800134T3 (da) | 2009-03-16 |
| JP4896883B2 (ja) | 2012-03-14 |
| WO2006040481A2 (fr) | 2006-04-20 |
| DE602005011316D1 (de) | 2009-01-08 |
| CA2582228C (fr) | 2018-07-31 |
| EP1800134B1 (de) | 2008-11-26 |
| EP1800134A2 (de) | 2007-06-27 |
| CA2582228A1 (fr) | 2006-04-20 |
| US20160091501A1 (en) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125258T1 (el) | Νεοι παραγοντες απεικονισης για ανιχνευση νευρολογικης δυσλειτουργιας | |
| ATE415632T1 (de) | Verfahren zur diagnose und behandlung von morbus crohn | |
| DK1811303T3 (da) | Forbindelser til behandling af irriteret tyktarm (IBS) | |
| EP1578371A4 (de) | Zusammensetzungen und verfahren für die tumor-diagnose und behandlung | |
| ATE440536T1 (de) | Verfahren zur diagnose, behandlung und prävention von knochenverlust | |
| EP1810026A4 (de) | B7-h1 und verfahren zur diagnose, prognose und behandlung von krebs | |
| WO2008134569A3 (en) | Diagnosis and treatment of inflammatory bowel disease in the puerto rican population | |
| ATE419390T1 (de) | Verfahren zur diagnose von bauchspeicheldrüsenkrebs | |
| DE60329165D1 (de) | Detektion und/oder beobachtung von synuclein-assoziierten krankheiten | |
| EP1572091A4 (de) | Zusammensetzungen und verfahren für die tumordiagnose und behandlung | |
| EP1718334A4 (de) | Verfahren zur diagnose und behandlung von präeklampsie oder eklampsie | |
| DE60137264D1 (de) | Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc) | |
| WO2007123723A3 (en) | Diagnosis and treatment of alzheimer's disease | |
| WO2008137762A3 (en) | Methods of diagnosis and treatment of crohn's disease | |
| WO2007011834A3 (en) | Compounds and method for the diagnosis and treatment of amyloid associated diseases | |
| ATE451477T1 (de) | Diagnose und überwachung von hepatozellulärem karzinom | |
| WO2004021008A3 (en) | Methods for detecting breast and ovarian cancer | |
| EP1742654A4 (de) | Anti-lfl2-antikörper zur diagnose, prognose und behandlung von krebs | |
| ATE514948T1 (de) | In vitro verfahren zur diagnose von neurodegenerativen erkrankungen | |
| ATE530667T1 (de) | Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit | |
| ATE546547T1 (de) | Diagnose der chronischen abstossung | |
| BRPI0409562A (pt) | tratamento de condições envolvendo placas amilóides | |
| FR2930036B1 (fr) | Procede de diagnostic d'une hypertension arterielle pulmonaire. | |
| BRPI0512948A (pt) | biomarcadores de mal de alzheimer | |
| BR0317404A (pt) | Variantes do fator xiia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |